Alpha Cognition Inc. announced it will present new clinical data on ZUNVEYL at the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025. The company will share three poster presentations detailing ZUNVEYL's pharmacokinetic profile.
The presentations include data on the bioequivalence of ZUNVEYL, a galantamine prodrug, to galantamine hydrobromide extended-release under steady-state conditions, and to galantamine hydrobromide immediate-release under fed and fasting conditions.
Additionally, data on the dose proportionality of ZUNVEYL over a dosage range of five to fifteen milligrams under fasting conditions will be presented. These studies are critical for demonstrating ZUNVEYL's consistent and predictable drug delivery, supporting its clinical utility.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.